London, June 15, 2026, 15:06 BST
- Smith & Nephew shares were little changed in London, while the FTSE 100 was lower.
- Investors are weighing a $500 million buyback, Cevian’s larger stake, and soft U.S. knee implant trends.
- The next major scheduled catalyst is the company’s second-quarter and first-half results on August 4, 2026.
Smith & Nephew plc shares were almost flat in London on Monday, with Hargreaves Lansdown showing the stock at a 1,134p sell price and 1,135p buy price, up 1.5p, or 0.13%, while the FTSE 100 was down 0.32%. The move was small, but it mattered because the medical technology group remains in a tug of war between shareholder-return support and doubts about the speed of its turnaround. The same quote showed a market value of about £9.61 billion, a price-to-earnings ratio of 14.94 and a 2.56% dividend yield. A price-to-earnings ratio, or P/E, compares a company’s share price with its earnings and is often used as a quick valuation check.
The latest support for the stock comes from Smith & Nephew’s active buyback. In a June 12 regulatory announcement, the company said it bought 1,204,120 ordinary shares between June 5 and June 11 through Merrill Lynch International, at a volume-weighted average price of £11.5122. Since May 8, it had bought 6,464,816 shares at a cost of $97.54 million under the programme. Buybacks can help a share price because they reduce the number of shares in the market and signal that management sees value in the stock, though they do not fix operational problems by themselves.
There is also an activist angle. A June 11 holding notice showed Cevian Capital II GP Limited had lifted its voting rights in Smith & Nephew to 12.074433%, up from 11.183442%, crossing the threshold on June 8. Activist investors can lift a stock when the market expects pressure for better margins, asset sales, or sharper capital allocation. They can also add uncertainty if investors start pricing in a more disruptive restructuring fight.
The bull case is straightforward: Smith & Nephew is returning cash, has activist pressure on management, and is still guiding for stronger growth later in the year. In its first-quarter update, the company reported revenue of $1.501 billion, underlying revenue growth of 3.1% and a new $500 million buyback. Underlying revenue growth strips out items such as currency moves and acquisition or disposal effects, giving investors a cleaner view of operating momentum. Chief executive Deepak Nath said “First-quarter performance was in line with our expectations” and that the company was “on track to deliver on our full year guidance.” Smith & Nephew kept 2026 guidance for about 6% underlying revenue growth, about 8% organic trading profit growth, around $800 million of free cash flow and adjusted return on invested capital above 10%, excluding the Integrity Orthopaedics impact. Smith Nephew
The bear case is that the guidance now depends heavily on second-half delivery. Smith & Nephew itself said growth in 2026 would be weighted toward the second half, helped by product launches, stabilisation in U.S. skin substitutes and an improving U.S. knee implants trend. That leaves room for disappointment. The company also still expects about $60 million of tariff impact and a $20 million to $40 million incremental hit from the skin-substitutes reimbursement reset. Weak U.S. knees are especially important because investors have long watched the orthopaedics franchise as a key test of whether the turnaround is real.
On valuation, the stock looks selectively attractive, not risk-free. Investors Chronicle data showed 16 analysts with a median 12-month target of 1,373.11p, about 21.19% above a last price of 1,133p, with three Buy ratings, four Outperform ratings, 11 Holds and no Sell ratings as of June 11. That suggests upside exists if Smith & Nephew proves the second-half recovery, keeps buying back stock and shows better knee momentum. But the large number of Hold ratings also says the market is not fully convinced. The next scheduled catalyst is the second-quarter and first-half results on August 4, 2026; before then, further Cevian disclosures, buyback updates and any signs around U.S. knees or skin-substitute reimbursement could explain the next rise or fall in the shares.
